No products in the cart.
2 Minute Medicine Rewind May 18, 2026
1. Delayed initiation of antibiotic therapy was strongly associated with treatment failure and prolonged hospitalization in hospitalized SSTI patients.
2. Comorbidity burden and socioeconomic disparities significantly influenced SSTI outcomes, highlighting the importance of individualized management and antimicrobial stewardship.
Evidence Rating Level: 3 (Average)
In this prospective observational study, Biyazin et al. evaluated determinants of treatment outcomes among 423 hospitalized patients with skin and soft tissue infections (SSTIs) at a tertiary referral hospital in Ethiopia. SSTIs are associated with substantial morbidity, prolonged hospitalization, and increasing antimicrobial resistance, particularly in settings with inconsistent antimicrobial stewardship and high rates of comorbidity. The investigators assessed early clinical response within 48–72 hours, treatment failure after 72 hours of therapy, hospital length of stay (HLOS), and in-hospital mortality. Multivariable logistic and linear regression analyses were used to identify predictors of treatment failure and prolonged hospitalization. Cellulitis was the most common diagnosis, and diabetes mellitus was the leading comorbidity. Mean HLOS was 13.5 days, 39.3% of patients achieved early clinical response, and 34.4% experienced treatment failure. Delayed antibiotic initiation beyond 12 hours, rural residence, coexisting illness, and higher comorbidity burden were independently associated with worse outcomes and longer hospitalization. Early antibiotic administration, oral step-down therapy, and higher socioeconomic status were associated with shorter HLOS and improved outcomes. The authors conclude that prompt empiric antibiotic therapy, effective source control, and strengthened antimicrobial stewardship are essential to improving SSTI outcomes, particularly in resource-limited settings.
1. Initiation of centrally acting analgesics in patients with osteoarthritis (OA) was associated with a higher long-term risk of total joint arthroplasty compared with SSRI initiation.
2. Management of comorbid depression may play an important role in OA symptom progression and surgical outcomes, potentially exceeding the benefit of centrally mediated analgesic effects alone.
Evidence Rating Level: 3 (Average)
This population-based cohort study evaluated whether centrally acting analgesics (CAAs), including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids, were associated with reduced progression of osteoarthritis (OA) compared with selective serotonin reuptake inhibitors (SSRIs). Using the UK IQVIA Medical Research Database, investigators conducted a propensity score–matched, new-user, active-comparator cohort study of adults aged 40–89 years with knee or hip OA between 2000 and 2021. A total of 11,734 incident CAA users were matched 1:1 with 11,734 SSRI initiators and followed for development of total joint arthroplasty (TJA), a surrogate marker of advanced OA progression. Median follow-up was approximately 9 years. Contrary to the study hypothesis, CAA initiation was associated with a significantly increased risk of TJA compared with SSRI initiation (HR 1.81, 95% CI 1.59–2.07). The association persisted after adjustment for confounders, competing risk of death, and treatment discontinuation (adjusted HR 1.48, 95% CI 1.22–1.80). Similar findings were observed in analyses of tricyclic antidepressants and gabapentinoids individually. In patients with both OA and depression, the association was attenuated and no longer statistically significant after full adjustment. The findings suggest that SSRIs, potentially through improved management of comorbid depression, may confer benefits on OA outcomes beyond direct analgesic mechanisms.
1. Physical frailty, particularly slow gait speed, was independently associated with a significantly increased risk of incident epilepsy in a large longitudinal cohort.
Evidence Rating Level: 2 (Good)
In this large prospective cohort study, Hu et al. investigated the association between physical frailty and incident epilepsy using data from 421,383 participants in the UK Biobank who were free of epilepsy and major neurologic disease at baseline. Physical frailty was assessed using a modified Fried frailty phenotype consisting of weight loss, exhaustion, low physical activity, slow gait speed, and low grip strength. Participants were categorized as non-frail, pre-frail, or frail and followed for a mean of 13.2 years for the development of epilepsy identified through linked health records. During follow-up, 2,752 incident epilepsy cases were identified. After adjustment for sociodemographic, lifestyle, and medical factors, prefrailty and frailty were independently associated with increased epilepsy risk, with hazard ratios of 1.29 and 1.81, respectively, compared with non-frail individuals. A dose-response relationship was observed between increasing frailty severity and epilepsy incidence. Among frailty components, slow gait speed demonstrated the strongest association with epilepsy risk. Biomarker analyses suggested that inflammatory, metabolic, endocrine, renal, hepatic, and hematologic pathways may partially mediate the frailty-epilepsy relationship, collectively explaining approximately 18.6% of the observed association. The authors conclude that physical frailty is an independent predictor of incident epilepsy and may represent a potentially modifiable target for epilepsy prevention in older adults.
1. Plasma p-tau217 was the strongest individual biomarker for predicting progression to Alzheimer’s disease dementia in patients with subjective cognitive decline.
2. A multimodal model combining cognitive assessment, plasma p-tau217, and APOE4 genotype provided excellent prognostic accuracy and may support early risk stratification in memory clinic populations.
Evidence Rating Level: 2 (Good)
This longitudinal observational study evaluated the prognostic utility of clinical, plasma, and imaging biomarkers for predicting cognitive decline in individuals with subjective cognitive decline (SCD) from the BioFINDER-1 and BioFINDER-2 cohorts. SCD is increasingly recognized as a preclinical stage of Alzheimer’s disease (AD), yet optimal risk stratification remains uncertain. The investigators included 469 participants with SCD (mean age 69.1 years; 51.4% female) who underwent baseline cognitive testing, APOE genotyping, plasma phosphorylated tau (p-tau217) measurement, and MRI assessment of cortical thickness, hippocampal volume, and white matter hyperintensity burden. Cox proportional hazards models were used to assess progression to all-cause dementia, AD dementia, and mild cognitive impairment (MCI). Over a mean follow-up of 4.0 years, 84 participants progressed to dementia, two-thirds of whom developed AD dementia. Progressors demonstrated worse baseline cognition, higher plasma p-tau217 levels, greater cortical and hippocampal atrophy, and higher white matter disease burden. Plasma p-tau217 was the strongest single predictor of AD dementia (C-index 0.86), while multimodal models incorporating cognition, plasma p-tau217, and APOE4 status achieved excellent predictive accuracy (C-index 0.91). MRI markers provided only marginal additional value for AD prediction, but improved prediction of all-cause dementia. The authors conclude that a clinically feasible multimodal approach combining cognitive testing, plasma p-tau217, and APOE4 status can accurately identify individuals with SCD at the highest risk for future dementia, particularly AD dementia.
Effect of intra-dialytic pedaling exercise on dialysis adequacy: A randomized controlled trial
1. A 4-week intradialytic pedalling exercise program was safe and well-tolerated but did not significantly improve dialysis adequacy measures.
Evidence Rating Level: 1 (Excellent)
This randomized controlled trial evaluated whether intradialytic pedaling exercise improves dialysis adequacy in adults with chronic kidney disease undergoing maintenance hemodialysis. Eighty-four patients from dialysis centers were randomized to either an intervention group performing supervised stationary pedaling during dialysis sessions or a control group receiving standard hemodialysis care. The intervention consisted of light-intensity cycling performed for 30 minutes during 4-hour dialysis sessions, three times weekly for four weeks. Dialysis adequacy was assessed using Kt/V, blood urea nitrogen (BUN), and weight changes before and after dialysis. After withdrawals, 79 participants completed the study. Although both groups demonstrated significant reductions in body weight and BUN over time, there were no statistically significant differences between the intervention and control groups in Kt/V, blood urea levels, or weight reduction. Post-intervention mean Kt/V values were 1.163 in the exercise group and 1.115 in controls (p=0.11). No adverse events related to exercise were reported, indicating that intradialytic cycling was feasible and safe in this patient population. The authors concluded that a short-term, low-intensity intradialytic pedaling program did not significantly improve dialysis adequacy. They suggested that longer-duration and higher-intensity exercise interventions may be required to produce clinically meaningful improvements in solute clearance and patient outcomes.
Image: PD
©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
RelatedReports
